Cefepime (CAS 88040-23-7)

Cefepime, a fourth-generation cephalosporin antibiotic, has been extensively investigated in scientific research for its mechanism of action and efficacy against a wide range of bacterial pathogens. Its mechanism of action primarily involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking and leading to bacterial cell lysis. Researchers have utilized cefepime as a tool to study bacterial resistance mechanisms, particularly in Gram-negative bacteria such as Pseudomonas aeruginosa and Enterobacter species, which are known for their intrinsic resistance to multiple antibiotics. Studies have focused on elucidating the structural determinants of cefepime′s interactions with PBPs and the molecular mechanisms underlying bacterial resistance to cephalosporin antibiotics. Additionally, cefepime′s pharmacokinetic properties and tissue distribution have been investigated to optimize dosing regimens. Beyond antimicrobial research, cefepime has found applications in biochemical and microbiological studies as a tool to investigate bacterial physiology, antibiotic resistance mechanisms, and the development of novel antimicrobial agents. With the continuous evolution of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, cefepime remains a valuable asset in scientific investigations aimed at understanding bacterial pathogenesis and developing effective strategies to combat antimicrobial resistance.